The polypill in the primary prevention of cardiovascular disease: Cost-effectiveness in the Dutch population

BMJ Open

Volumn 1, Issue 2, 2011, Pages

  Van Gils, Paul F ^a   Over, Eelco A B ^a   Hamberg Van Reenen, Heleen H ^a   De Wit, G Ardine ^a,b   Van Den Berg, Matthijs ^a   Schuit, Albertine J ^a,c   Engelfriet, Peter M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855508423     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000363     Document Type: Article

References (52)

1. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
2. AHA. Cardiovascular Disease Statistics. Dallas, Texas, USA: American Heart Association, 2010.
3. CBS. Causes of Death 2009, Short List. The Hague, the Netherlands: CBS, 2010.
4. Vaartjes I, van Dis I, Visseren FLJ, et al. Chapter 1: Cardiovascular Disease in the Netherlands (in Dutch). Cardiovascular Diseases in the Netherlands, 2009. Den Haag, The Netherlands: Dutch Heartfoundation, 2009.
5. Zhao G, Ford ES, Li C, et al. Are United States adults with coronary heart disease meeting physical activity recommendations? Am J Cardiol 2008;101:557-61.
6. Garner JB. Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol 2010;105:1495-501.
7. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009;10:2973-85.
8. Corrao G, Conti V, Merlino L, et al. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 2010;32:300-10.
9. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 (Suppl 2):E1-40. (Pubitemid 47342420)
10. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003. (Pubitemid 36712275)
11. Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010;122:2078-88.
12. Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373:1341-51.
13. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
14. van Dis I, Kromhout D, Geleijnse JM, et al. Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil 2010;17:244-9.
15. Hoogenveen RT, van Baal PH, Boshuizen HC. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. Math Med Biol 2010;27:1-19.
16. Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, et al. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care 2007;30:128-34. (Pubitemid 46052510)
17. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.
18. CBO. Dutch Guideline Cardiovascular Risk Management. In: CBO DIfHI, ed. Utrecht, The Netherlands: Dutch Institute for Healthcare Improvement CBO, 2006.
19. Baal PHM, Feenstra TL, Hoogenveen RT, et al. Cost-Efectiveness analysis with the RIVM Chronic Disease Model. Bilthoven, Netherlands: Dutch National Institute for Public Health and the Environment, 2005.
20. Slobbe LCJ, Kommer GJ, Smit JM, et al. Cost-of-illness in the Netherlands 2003. Bilthoven, Netherlands: National Institute for Public Health and the Environment, 2006.
21. Melse JM, Essink-Bot ML, Kramers PG, et al. A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. Am J Public Health 2000;90:1241-7. (Pubitemid 30497377)
22. Stouthard MEA, Essink-Bot ML, Bonsel GJ. Disability weights for diseases: a modified protocol and results for a Western European region. Eur J Public Health 2000;10:24-30. (Pubitemid 30182899)
23. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-3. (Pubitemid 28512100)
24. van Baal PH, Hoeymans N, Hoogenveen RT, et al. Disability weights for comorbidity and their influence on health-adjusted life expectancy. Popul Health Metr 2006;4:1.
25. Verschuren WM, Blokstra A, Picavet HS, et al. Cohort profile: the Doetinchem Cohort Study. Int J Epidemiol 2008;37:1236-41.
26. CBS. Statistics Netherlands. The Hague, the Netherlands: CBS, 2010.
27. Chapman RH, Petrilla AA, Benner JS, et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging 2008;25:885-92.
28. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427.
29. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Bmj 2008;336:1121-3. (Pubitemid 351731743)
30. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-19. (Pubitemid 40973424)
31. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;(1): CD004816.
32. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
33. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
34. Weng TC, Yang YH, Lin SJ, et al. A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139-51.
35. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
36. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Manual for Costing Research. Methods and Directive Prices For Economic Evaluation In Health Care (In Dutch). Diemen: Institute for Medical Technology Assessment. Erasmus MC, 2010.
37. CVZ. Medicijnkosten. Diemen: CVZ, 2010.
38. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sexspecific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13.
39. Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med 2007;167:290-5.
40. van den Berg M, de Wit GA, Vijgen SM, et al. [Cost-effectiveness of prevention: opportunities for public health policy in the Netherlands] (In Dutch). Ned Tijdschr Geneeskd 2008;152:1329-34.
41. Franco OH, Steyerberg EW, de Laet C. The polypill: at what price would it become cost effective? J Epidemiol Community Health 2006;60:213-17. (Pubitemid 43288626)
42. Wald NJ, Simmonds M, Morris JK. Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One 2011;6:e18742.
43. van de Kerkhof RM, Godefrooij MB, Wouda PJ, et al. [Cardiometabolic risk factors detected with a preventative screening programme] (In Dutch). Ned Tijdschr Geneeskd 2010;154:A1860.
44. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33.
45. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-14.
46. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-83. (Pubitemid 47216196)
47. Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich) 2010;12:40-6.
48. WHO. Adherence To Long-Term Therapies: Evidence For Action. Geneva, Switzerland: World Health Organization, 2003.
49. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310. (Pubitemid 32804122)
50. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-8. (Pubitemid 34925341)
51. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71. (Pubitemid 32973555)
52. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72. (Pubitemid 34073943)